Prospective randomized trial comparing two doses of rabbit anti-thymocyte globulin in patients with severe aplastic anaemia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Narita, Atsushi | - |
dc.contributor.author | Zhu, Xiaofan | - |
dc.contributor.author | Muramatsu, Hideki | - |
dc.contributor.author | Chen, Xiaojuan | - |
dc.contributor.author | Guo, Ye | - |
dc.contributor.author | Yang, Wenyu | - |
dc.contributor.author | Zhang, Jingliao | - |
dc.contributor.author | Liu, Fang | - |
dc.contributor.author | Jang, Jun H. | - |
dc.contributor.author | Kook, Hoon | - |
dc.contributor.author | Kim, Hawk | - |
dc.contributor.author | Usuki, Kensuke | - |
dc.contributor.author | Yamazaki, Hirohito | - |
dc.contributor.author | Takahashi, Yoshiyuki | - |
dc.contributor.author | Nakao, Shinji | - |
dc.contributor.author | Lee, Jong Wook | - |
dc.contributor.author | Kojima, Seiji | - |
dc.date.available | 2020-02-27T02:21:54Z | - |
dc.date.created | 2020-02-04 | - |
dc.date.issued | 2019-10 | - |
dc.identifier.issn | 0007-1048 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/963 | - |
dc.description.abstract | The treatment of choice for patients with severe aplastic anaemia (SAA) includes immunosuppressive therapy (IST) with anti-thymocyte globulin (ATG) and ciclosporin A. However, the optimal dose for rabbit ATG has yet to be established. We herein report the first prospective, randomized, multicentre study comparing two doses of rabbit ATG in patients with SAA. Patients with SAA who required initial IST in Japan (n = 89), China (n = 85) and Korea (n = 48) were enrolled between May 2012 and October 2017. A 1:1 block randomization was employed for two doses of rabbit ATG. In total, 222 patients were randomized, with 112 patients receiving 2 center dot 5 mg/kg and 110 receiving 3 center dot 5 mg/kg of rabbit ATG for 5 days. The primary endpoint was the haematological response at day 180. After 6 months, no significant difference in response rates was observed between the 2 center dot 5 and 3 center dot 5 mg/kg groups (49% vs. 48%, P = 0 center dot 894). Overall survival at 3 years was similar between the two groups [85% (95% confidence interval [CI], 76%-91%) vs. 91% (95% CI, 82%-96%); P = 0 center dot 107]. The current study revealed no significant differences in the efficacy and safety between the 2 center dot 5 and 3 center dot 5 mg/kg doses of rabbit ATG in patients with SAA. Trial registration: UMIN000011134. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.relation.isPartOf | BRITISH JOURNAL OF HAEMATOLOGY | - |
dc.subject | BONE-MARROW-TRANSPLANTATION | - |
dc.subject | ANTITHYMOCYTE GLOBULIN | - |
dc.subject | IMMUNOSUPPRESSIVE THERAPY | - |
dc.subject | 1ST-LINE TREATMENT | - |
dc.subject | CELL TRANSPLANTATION | - |
dc.subject | CYCLOSPORINE-A | - |
dc.subject | EUROPEAN GROUP | - |
dc.subject | HORSE | - |
dc.subject | CHILDREN | - |
dc.subject | GUIDELINES | - |
dc.title | Prospective randomized trial comparing two doses of rabbit anti-thymocyte globulin in patients with severe aplastic anaemia | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000489280300020 | - |
dc.identifier.doi | 10.1111/bjh.16055 | - |
dc.identifier.bibliographicCitation | BRITISH JOURNAL OF HAEMATOLOGY, v.187, no.2, pp.227 - 237 | - |
dc.identifier.scopusid | 2-s2.0-85067452875 | - |
dc.citation.endPage | 237 | - |
dc.citation.startPage | 227 | - |
dc.citation.title | BRITISH JOURNAL OF HAEMATOLOGY | - |
dc.citation.volume | 187 | - |
dc.citation.number | 2 | - |
dc.contributor.affiliatedAuthor | Kim, Hawk | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | severe aplastic anaemia | - |
dc.subject.keywordAuthor | dose | - |
dc.subject.keywordAuthor | rabbit ATG | - |
dc.subject.keywordAuthor | immunosuppressive therapy | - |
dc.subject.keywordPlus | BONE-MARROW-TRANSPLANTATION | - |
dc.subject.keywordPlus | ANTITHYMOCYTE GLOBULIN | - |
dc.subject.keywordPlus | IMMUNOSUPPRESSIVE THERAPY | - |
dc.subject.keywordPlus | 1ST-LINE TREATMENT | - |
dc.subject.keywordPlus | CELL TRANSPLANTATION | - |
dc.subject.keywordPlus | CYCLOSPORINE-A | - |
dc.subject.keywordPlus | EUROPEAN GROUP | - |
dc.subject.keywordPlus | HORSE | - |
dc.subject.keywordPlus | CHILDREN | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.